Measure modulations of immune checkpoint markers
Thermo Fisher Scientific offers a wide selection of ELISA and multiplex immunoassay solutions for immuno-oncology research that enable the measurement of soluble immune checkpoint molecules and other immune-related targets in serum, plasma, and culture supernatant for human and mouse.
Overview of immuno-oncology and immune checkpoint markers
Immuno-oncology is a type of immunotherapy approach that uses the body’s immune system to help battle cancer—a different approach that goes beyond traditional methods such as surgery, chemotherapy, and radiation.
Many recent drug development strategies have been to target immune checkpoint markers to enhance anti-tumor immunity. Immune checkpoints are cell pathways important in maintaining a normal immune response and protecting tissues from damage when the immune system is activated (Figure 1). Cancer cells dysregulate immune checkpoints and use them as a mechanism of immune resistance. For example, PD-1 masks cancer cells from T-cell recognition, thereby preventing the attack by T cells.
Cell signaling is a complex communication process to coordinate cell activities. Cell surface receptors respond to the microenvironment and trigger signal transduction cascades within the cell. The targets of such signaling pathways commonly include transcription factors that function to regulate gene expression. Errors in signaling interactions and cellular information processes are responsible for many diseases such as cancer and autoimmunity.
Cytokines are immune cell messengers that stimulate immune effector cells and stromal cells in tumors and also increase the recognition of tumor cells by cytotoxic effector cells. Investigations using animal models have revealed that cytokines display anti-tumor activity, resulting in an increased interest in the use of cytokines as a basis for cancer therapy. Many cytokines, such as GM-CSF, IL-7, IL-12, IL-15, IL-18, and IL-21, are in clinical trials for patients with advanced cancers. Pre-clinical research has focused on being able to neutralize cytokines that act to suppress the immune response, for example IL-10 and TGF-β. Adoptive cell therapy is an approach that makes modification to T cells to focus them on killing tumor cells, while controlling the cytokine response for optimal effect.
Figure 1. The cancer immunity cycle. Immune checkpoint inhibitors are targets for biotherapeutic antibodies.
Immuno-oncology ELISA kits
Detecting and measuring immune checkpoint markers could be a promising pathway to better develop treatment strategies. For example, CTLA-4 plays a role during the priming of a T cell by an antigen-presenting cell. Blocking of the CTLA-4 receptor by an antibody allows T cell activation, resulting in an anticancer immune response. Correlation has been observed with positive health benefits and elevated levels of quantified soluble CTLA-4 (sCTLA4) concentrations by ELISA in antibody-therapy treated subjects (Figure 2).
Whether you are studying CTLA-4 or other immune checkpoint markers, Invitrogen ELISA Kits provide a specific and sensitive method to measure and monitor these biomarkers in serum, plasma, or cell culture supernatants.
Popular immuno-oncology protein targets and ELISA performance data
View all ELISA kits for the following popular targets:
Figure 2. Serum CTLA-4 levels in melanoma patient samples. Statistical analysis following ipilimumab (CTLA-4 antibody drug) therapy shows correlation between responders and higher concentration levels of CTLA-4 in serum samples from melanoma patients using Invitrogen CTLA-4 (Soluble) Human ELISA Kit.
Reprinted from: Leung A.M., et al. Clinical benefit from ipilimumab therapy in melanoma patients may be associated with serum CTLA4 levels. Frontiers in Oncology 4:110 (2014).
Immuno-oncology ProQuantum high sensitivity immunoassays
Invitrogen ProQuantum high-sensitivity immunoassays are designed for easy-to-run, high-performance, protein detection with no proprietary instrument to purchase. Utilizing proximity-based amplification technology, ProQuantum assays offer the analyte specificity of antibody-antigen binding with the signal detection and amplification capabilities of qPCR. ProQuantum assays can also typically detect lower levels of protein with lower sample consumption than traditional methods. This can be particularly important when handling very limited volumes of precious samples from blood or tumor extracts. Limited sample volumes also present a challenge to detect very low levels of protein, but our ProQuantum technology solves that by amplifying the signal beyond the capability of other available methods. See our selection of sensitive assays for cytokines (Table 1), which play an important role in immuno-oncology and checkpoint modulation. Click below to see our complete selection of assays.
Find cytokine-related ProQuantum assays
Table 1. Examples of ProQuantum immunoassays for immuno-oncology research.
| Cytokine | Primary cell source | Primary target cell | Biological activity |
|---|---|---|---|
| GM-CSF | T cells, macrophages, endothelial cells, fibroblasts, mast cells | Bone marrow, progenitor cells, DC, macrophages NKT cells | Promotes antigen presentation, T cell homeostasis, hematopoietic cell growth factor |
| IL-1 | Monocytes, macrophages, fibroblasts, epithelial cells, endothelial cells, astrocytes | T cells, B cells, endothelial cells, hypothalamus, liver | Co-stimulation, cell activation, inflammation, fever, acute phase reactant |
| IL-2 | T cells, NK cells | T cells, NK cells, B cells, monocytes | Cell growth/activation |
| IL-3 | T cells | Bone marrow progenitor cells | Cell growth and differentiation |
| IL-4 | T cells | T cells, B cells | Th2 differentiation, cell growth/activation, IgE isotype switching |
| IL-5 | T cells | B cells, eosinophils | Cell growth/activation |
| IL-6 | T cells, macrophages, fibroblasts | T cells, B cells, liver | Co-stimulation, cell growth/activation, acute phase reactant |
| IL-7 | Fibroblasts, bone marrow stromal cells | Immature lymphoid, progenitors | T cell survival, proliferation, homeostasis, B cell development |
| IL-8 | Macrophages, epithelial cells, platelets | Neutrophils | Activation, chemotaxis |
| IL-10 | Th2 T cells | Macrophages, T cells | Inhibits antigen-presenting cells, inhibits cytokine production |
| IL-12 | Macrophages, NK cells | T cells | Th1 differentiation |
| IL-15 | Monocytes | T cells, NK cells | Cell growth/activation, NK cell development, blocks apoptosis |
| IL-18 | Macrophages | T cells, NK cells, B cells | Cell growth/activation, inflammation |
| IL-21 | CD4+ T cells, NKT cells | NK cells, T cells, B cells | Cell growth/activation, control of allergic responses and viral infections |
| IL-23 | Antigen-presenting cells | T cells, NK cells, DC | Chronic inflammation, promotes Th17 cells |
| IFN-α | Plasmacytoid DC, NK cells, T cells, B cells, macrophages, fibroblasts, endothelial cells, osteoblasts | Macrophages, NK cells | Anti-viral, enhances MHC expression |
| IFN-γ | T cells, NK cells, NKT cells | Monocytes, macrophages, endothelial cells, tissue cells | Cell growth/activation, enhances MHC expression |
| TGF-β | T cells, macrophages | T cells | Inhibits cell growth/activation |
| TNF- α | Macrophages, T cells | T cells, B cells, endothelial cells, hypothalamus, liver | Co-stimulation, cell activation, inflammation, fever, acute phase reactant |
References: S Lee and K Margolin, Cytokines in Cancer Immunotherapy Cancers (Basel). 2011 Dec; 3(4): 3856–3893.1.
Immuno-oncology ProcartaPlex multiplex immunoassays
The Invitrogen ProcartaPlex Immuno-Oncology Checkpoint Panels allow for the simultaneous detection of up to 38 soluble immune checkpoint molecules and help provide a more comprehensive picture of cancer immunity. Our Immuno-Oncology Checkpoint panels (Table 2) have been specifically designed and optimized for cerebral spinal fluid, serum, and plasma samples. Use preconfigured panels below or select from single targets to create your own custom panel to study either human or mouse immune checkpoint biomarkers.
Watch these on-demand webinars:
- Jun 2021 Panel Presentation: xMAP® INTELLIFLEX and Immunoassay Innovations: Tools to advance immuno-oncology research
Presented by Wilco de Jager, PhD, Sr. Field Applications Scientist, Luminex and Sigrun Badrnya, Product Development Manager, Thermo Fisher Scientific - Sep 2018 Poster Presentation: Development of Multiplex xMAP® Technology-Based Assays for Simultaneous Detection of Soluble Checkpoint Molecules Involved in Anti-Cancer Immune Response
Presented by Susanne Oehler, PhD, Senior Manager, Research and Development, Antibodies and Immunoassays, Thermo Fisher Scientific
Preconfigured immuno-oncology multiplex immunoassay panels and performance data
Figure 3. Detection of multiple immune checkpoint inhibitors in human and mouse samples. Immuno-Oncology Checkpoint 4-Plex Mouse ProcartaPlex Panel 1 (top) and Immuno-Oncology Checkpoint 7-Plex Mouse ProcartaPlex Panel 2 (bottom) were tested using homogenized MC38 or TC-1 derived tumor tissue extract from C57BI/6 mice. Tissue extracts were homogenized in RIPA buffer using a proteinase inhibitor. Some mice were not treated (control) and others received a treatment. The tumor tissue was removed at different time points after treatment. Differences were observed between the treated vs control groups, suggesting a role for these proteins in tumor progression. Data provided by a collaborator.
Table 2. Preconfigured ProcartaPlex multiplex immunoassay panels for immuno-oncology.
| Human multiplex immune checkpoint panels | ||
| Cat. No. | Name | Size |
| EPX14A-15803-901 | Immuno-Oncology Checkpoint 14-Plex Human ProcartaPlex Panel 1 (Immune stimulatory: CD27 [27], CD28 [15], CD137 (4-1BB) [26], GITR [57], HVEM [36] Immune inhibitory: BTLA [52], CD80 [61], CD152 (CTLA4) [33], IDO [46], LAG-3 [47], PD-1 [65], PD-L1 [66], PD-L2 [67], TIM-3 [14]) | 96 tests |
| EPX140-15815-901 | Immuno-Oncology Checkpoint 14-Plex Human ProcartaPlex Panel 2 (Activating: MICA [18], MICB [21], Perforin [53], ULBP-1 [73], ULBP-3 [77], ULBP-4 [78]Inhibitory: Arginase-1 [51], CD73 (NT5E) [30], CD96 (Tactile) [35], E-Cadherin [44], Nectin-2 [29], PVR [56], Siglec-7 [12], Siglec-9 [13]) | 96 tests |
| EPX100-15820-901 | Immuno-Oncology Checkpoint 10-Plex Human ProcartaPlex Panel 3 (B7-H6 [42], CD276 (B7-H3) [72], CD47 (IAP) [74], CD48 (BLAST-1) [19], CD134 (OX40) [55], Galectin-9 [38], ICOS Ligand (B7-H2) [34], TIMD-4 [39], S100A8/A9 [76], VISTA (B7-H5) [64]) | 96 tests |
| Mouse multiplex immune checkpoint panels | ||
| Cat. No. | Name | Size |
| EPX040-20830-901 | Immuno-Oncology Checkpoint 4-Plex Mouse ProcartaPlex Panel 1 (BTLA [61], CD27 [75], LAG-3 [44], TIM-3 [46]) | 96 tests |
| EPX070-20835-901 | Immuno-Oncology Checkpoint 7-Plex Mouse ProcartaPlex Panel 2 (CD137L (4-1BBL) [74], CD152 (CTLA4) [77], CD276 (B7-H3) [67], CD80 [15], PD-1 [73], PD-L1 [29], PD-L2 [53]) | 96 tests |
Multiplex gene expression and protein assays—immuno-oncology research
QuantiGene RNA gene expression assays provide a fast and high-throughput solution for multiplexed gene expression quantitation, with simultaneous measurement of up to 80 genes of interest in a single well of a 96- or 384-well plate. The QuantiGene Plex assay is based on hybridization and incorporates branched DNA (bDNA) technology, which uses signal amplification rather than target amplification for direct measurement of RNA transcripts. The assay is run on the Luminex platform, has a simple workflow, and does not require RNA purification. These features allow the user to merge the QuantiGene workflow for gene expression profiling with the ProcartaPlex workflow for protein quantitation (Figure 5) using the same sample.
For example, tumor cells are heavily influenced by the cytokines secreted in the tumor microenvironment. With multiplexing capabilities of up to 80 analytes, QuantiGene Plex gene expression and ProcartaPlex multiplex assays enable full characterization of a given cytokine milieu on the transcript (RNA) and protein level (Figure 6).
Learn more about QuantiGene RNA Assays for Gene Expression Profiling
Read our publication in Methods, (2019) Vol. 158, p27-33: Multiplexing protein and gene level measurements on a single Luminex platform
Figure 6. Simultaneous analysis of protein and gene expression from the same sample. Human histocytic lymphoma cells, U-937, were treated with 1 μg/mL of LPS for 48 hours or with 1 μg/mL of PMA for 24 hours. At the end of the incubation period cell supernatants were collected, and the corresponding cells were lysed. The supernatants containing protein were analyzed for 20 different cytokines using the Invitrogen Th1/Th2 Cytokine & Chemokine 20-Plex Human ProcartaPlex Panel 1. The cell lysates containing RNA were analyzed for 36 different cytokines, chemokines, growth factors, and housekeeping genes using a QuantiGene Plex custom panel which can be designed using the QuantiGene Panel Configurator. The assays were run on the Invitrogen Luminex xMAP™ INTELLIFLEX DR-SE System. Data for IL-8 (CXCL8) and MCP-1 (CCL2) are shown here as an example. Data analysis was performed using the ProcartaPlex and QuantiGene Plex Data Analysis Apps on the Thermo Fisher Connect platform.
Overview of immuno-oncology and immune checkpoint markers
Immuno-oncology is a type of immunotherapy approach that uses the body’s immune system to help battle cancer—a different approach that goes beyond traditional methods such as surgery, chemotherapy, and radiation.
Many recent drug development strategies have been to target immune checkpoint markers to enhance anti-tumor immunity. Immune checkpoints are cell pathways important in maintaining a normal immune response and protecting tissues from damage when the immune system is activated (Figure 1). Cancer cells dysregulate immune checkpoints and use them as a mechanism of immune resistance. For example, PD-1 masks cancer cells from T-cell recognition, thereby preventing the attack by T cells.
Cell signaling is a complex communication process to coordinate cell activities. Cell surface receptors respond to the microenvironment and trigger signal transduction cascades within the cell. The targets of such signaling pathways commonly include transcription factors that function to regulate gene expression. Errors in signaling interactions and cellular information processes are responsible for many diseases such as cancer and autoimmunity.
Cytokines are immune cell messengers that stimulate immune effector cells and stromal cells in tumors and also increase the recognition of tumor cells by cytotoxic effector cells. Investigations using animal models have revealed that cytokines display anti-tumor activity, resulting in an increased interest in the use of cytokines as a basis for cancer therapy. Many cytokines, such as GM-CSF, IL-7, IL-12, IL-15, IL-18, and IL-21, are in clinical trials for patients with advanced cancers. Pre-clinical research has focused on being able to neutralize cytokines that act to suppress the immune response, for example IL-10 and TGF-β. Adoptive cell therapy is an approach that makes modification to T cells to focus them on killing tumor cells, while controlling the cytokine response for optimal effect.
Figure 1. The cancer immunity cycle. Immune checkpoint inhibitors are targets for biotherapeutic antibodies.
Immuno-oncology ELISA kits
Detecting and measuring immune checkpoint markers could be a promising pathway to better develop treatment strategies. For example, CTLA-4 plays a role during the priming of a T cell by an antigen-presenting cell. Blocking of the CTLA-4 receptor by an antibody allows T cell activation, resulting in an anticancer immune response. Correlation has been observed with positive health benefits and elevated levels of quantified soluble CTLA-4 (sCTLA4) concentrations by ELISA in antibody-therapy treated subjects (Figure 2).
Whether you are studying CTLA-4 or other immune checkpoint markers, Invitrogen ELISA Kits provide a specific and sensitive method to measure and monitor these biomarkers in serum, plasma, or cell culture supernatants.
Popular immuno-oncology protein targets and ELISA performance data
View all ELISA kits for the following popular targets:
Figure 2. Serum CTLA-4 levels in melanoma patient samples. Statistical analysis following ipilimumab (CTLA-4 antibody drug) therapy shows correlation between responders and higher concentration levels of CTLA-4 in serum samples from melanoma patients using Invitrogen CTLA-4 (Soluble) Human ELISA Kit.
Reprinted from: Leung A.M., et al. Clinical benefit from ipilimumab therapy in melanoma patients may be associated with serum CTLA4 levels. Frontiers in Oncology 4:110 (2014).
Immuno-oncology ProQuantum high sensitivity immunoassays
Invitrogen ProQuantum high-sensitivity immunoassays are designed for easy-to-run, high-performance, protein detection with no proprietary instrument to purchase. Utilizing proximity-based amplification technology, ProQuantum assays offer the analyte specificity of antibody-antigen binding with the signal detection and amplification capabilities of qPCR. ProQuantum assays can also typically detect lower levels of protein with lower sample consumption than traditional methods. This can be particularly important when handling very limited volumes of precious samples from blood or tumor extracts. Limited sample volumes also present a challenge to detect very low levels of protein, but our ProQuantum technology solves that by amplifying the signal beyond the capability of other available methods. See our selection of sensitive assays for cytokines (Table 1), which play an important role in immuno-oncology and checkpoint modulation. Click below to see our complete selection of assays.
Find cytokine-related ProQuantum assays
Table 1. Examples of ProQuantum immunoassays for immuno-oncology research.
| Cytokine | Primary cell source | Primary target cell | Biological activity |
|---|---|---|---|
| GM-CSF | T cells, macrophages, endothelial cells, fibroblasts, mast cells | Bone marrow, progenitor cells, DC, macrophages NKT cells | Promotes antigen presentation, T cell homeostasis, hematopoietic cell growth factor |
| IL-1 | Monocytes, macrophages, fibroblasts, epithelial cells, endothelial cells, astrocytes | T cells, B cells, endothelial cells, hypothalamus, liver | Co-stimulation, cell activation, inflammation, fever, acute phase reactant |
| IL-2 | T cells, NK cells | T cells, NK cells, B cells, monocytes | Cell growth/activation |
| IL-3 | T cells | Bone marrow progenitor cells | Cell growth and differentiation |
| IL-4 | T cells | T cells, B cells | Th2 differentiation, cell growth/activation, IgE isotype switching |
| IL-5 | T cells | B cells, eosinophils | Cell growth/activation |
| IL-6 | T cells, macrophages, fibroblasts | T cells, B cells, liver | Co-stimulation, cell growth/activation, acute phase reactant |
| IL-7 | Fibroblasts, bone marrow stromal cells | Immature lymphoid, progenitors | T cell survival, proliferation, homeostasis, B cell development |
| IL-8 | Macrophages, epithelial cells, platelets | Neutrophils | Activation, chemotaxis |
| IL-10 | Th2 T cells | Macrophages, T cells | Inhibits antigen-presenting cells, inhibits cytokine production |
| IL-12 | Macrophages, NK cells | T cells | Th1 differentiation |
| IL-15 | Monocytes | T cells, NK cells | Cell growth/activation, NK cell development, blocks apoptosis |
| IL-18 | Macrophages | T cells, NK cells, B cells | Cell growth/activation, inflammation |
| IL-21 | CD4+ T cells, NKT cells | NK cells, T cells, B cells | Cell growth/activation, control of allergic responses and viral infections |
| IL-23 | Antigen-presenting cells | T cells, NK cells, DC | Chronic inflammation, promotes Th17 cells |
| IFN-α | Plasmacytoid DC, NK cells, T cells, B cells, macrophages, fibroblasts, endothelial cells, osteoblasts | Macrophages, NK cells | Anti-viral, enhances MHC expression |
| IFN-γ | T cells, NK cells, NKT cells | Monocytes, macrophages, endothelial cells, tissue cells | Cell growth/activation, enhances MHC expression |
| TGF-β | T cells, macrophages | T cells | Inhibits cell growth/activation |
| TNF- α | Macrophages, T cells | T cells, B cells, endothelial cells, hypothalamus, liver | Co-stimulation, cell activation, inflammation, fever, acute phase reactant |
References: S Lee and K Margolin, Cytokines in Cancer Immunotherapy Cancers (Basel). 2011 Dec; 3(4): 3856–3893.1.
Immuno-oncology ProcartaPlex multiplex immunoassays
The Invitrogen ProcartaPlex Immuno-Oncology Checkpoint Panels allow for the simultaneous detection of up to 38 soluble immune checkpoint molecules and help provide a more comprehensive picture of cancer immunity. Our Immuno-Oncology Checkpoint panels (Table 2) have been specifically designed and optimized for cerebral spinal fluid, serum, and plasma samples. Use preconfigured panels below or select from single targets to create your own custom panel to study either human or mouse immune checkpoint biomarkers.
Watch these on-demand webinars:
- Jun 2021 Panel Presentation: xMAP® INTELLIFLEX and Immunoassay Innovations: Tools to advance immuno-oncology research
Presented by Wilco de Jager, PhD, Sr. Field Applications Scientist, Luminex and Sigrun Badrnya, Product Development Manager, Thermo Fisher Scientific - Sep 2018 Poster Presentation: Development of Multiplex xMAP® Technology-Based Assays for Simultaneous Detection of Soluble Checkpoint Molecules Involved in Anti-Cancer Immune Response
Presented by Susanne Oehler, PhD, Senior Manager, Research and Development, Antibodies and Immunoassays, Thermo Fisher Scientific
Preconfigured immuno-oncology multiplex immunoassay panels and performance data
Figure 3. Detection of multiple immune checkpoint inhibitors in human and mouse samples. Immuno-Oncology Checkpoint 4-Plex Mouse ProcartaPlex Panel 1 (top) and Immuno-Oncology Checkpoint 7-Plex Mouse ProcartaPlex Panel 2 (bottom) were tested using homogenized MC38 or TC-1 derived tumor tissue extract from C57BI/6 mice. Tissue extracts were homogenized in RIPA buffer using a proteinase inhibitor. Some mice were not treated (control) and others received a treatment. The tumor tissue was removed at different time points after treatment. Differences were observed between the treated vs control groups, suggesting a role for these proteins in tumor progression. Data provided by a collaborator.
Table 2. Preconfigured ProcartaPlex multiplex immunoassay panels for immuno-oncology.
| Human multiplex immune checkpoint panels | ||
| Cat. No. | Name | Size |
| EPX14A-15803-901 | Immuno-Oncology Checkpoint 14-Plex Human ProcartaPlex Panel 1 (Immune stimulatory: CD27 [27], CD28 [15], CD137 (4-1BB) [26], GITR [57], HVEM [36] Immune inhibitory: BTLA [52], CD80 [61], CD152 (CTLA4) [33], IDO [46], LAG-3 [47], PD-1 [65], PD-L1 [66], PD-L2 [67], TIM-3 [14]) | 96 tests |
| EPX140-15815-901 | Immuno-Oncology Checkpoint 14-Plex Human ProcartaPlex Panel 2 (Activating: MICA [18], MICB [21], Perforin [53], ULBP-1 [73], ULBP-3 [77], ULBP-4 [78]Inhibitory: Arginase-1 [51], CD73 (NT5E) [30], CD96 (Tactile) [35], E-Cadherin [44], Nectin-2 [29], PVR [56], Siglec-7 [12], Siglec-9 [13]) | 96 tests |
| EPX100-15820-901 | Immuno-Oncology Checkpoint 10-Plex Human ProcartaPlex Panel 3 (B7-H6 [42], CD276 (B7-H3) [72], CD47 (IAP) [74], CD48 (BLAST-1) [19], CD134 (OX40) [55], Galectin-9 [38], ICOS Ligand (B7-H2) [34], TIMD-4 [39], S100A8/A9 [76], VISTA (B7-H5) [64]) | 96 tests |
| Mouse multiplex immune checkpoint panels | ||
| Cat. No. | Name | Size |
| EPX040-20830-901 | Immuno-Oncology Checkpoint 4-Plex Mouse ProcartaPlex Panel 1 (BTLA [61], CD27 [75], LAG-3 [44], TIM-3 [46]) | 96 tests |
| EPX070-20835-901 | Immuno-Oncology Checkpoint 7-Plex Mouse ProcartaPlex Panel 2 (CD137L (4-1BBL) [74], CD152 (CTLA4) [77], CD276 (B7-H3) [67], CD80 [15], PD-1 [73], PD-L1 [29], PD-L2 [53]) | 96 tests |
Multiplex gene expression and protein assays—immuno-oncology research
QuantiGene RNA gene expression assays provide a fast and high-throughput solution for multiplexed gene expression quantitation, with simultaneous measurement of up to 80 genes of interest in a single well of a 96- or 384-well plate. The QuantiGene Plex assay is based on hybridization and incorporates branched DNA (bDNA) technology, which uses signal amplification rather than target amplification for direct measurement of RNA transcripts. The assay is run on the Luminex platform, has a simple workflow, and does not require RNA purification. These features allow the user to merge the QuantiGene workflow for gene expression profiling with the ProcartaPlex workflow for protein quantitation (Figure 5) using the same sample.
For example, tumor cells are heavily influenced by the cytokines secreted in the tumor microenvironment. With multiplexing capabilities of up to 80 analytes, QuantiGene Plex gene expression and ProcartaPlex multiplex assays enable full characterization of a given cytokine milieu on the transcript (RNA) and protein level (Figure 6).
Learn more about QuantiGene RNA Assays for Gene Expression Profiling
Read our publication in Methods, (2019) Vol. 158, p27-33: Multiplexing protein and gene level measurements on a single Luminex platform
Figure 6. Simultaneous analysis of protein and gene expression from the same sample. Human histocytic lymphoma cells, U-937, were treated with 1 μg/mL of LPS for 48 hours or with 1 μg/mL of PMA for 24 hours. At the end of the incubation period cell supernatants were collected, and the corresponding cells were lysed. The supernatants containing protein were analyzed for 20 different cytokines using the Invitrogen Th1/Th2 Cytokine & Chemokine 20-Plex Human ProcartaPlex Panel 1. The cell lysates containing RNA were analyzed for 36 different cytokines, chemokines, growth factors, and housekeeping genes using a QuantiGene Plex custom panel which can be designed using the QuantiGene Panel Configurator. The assays were run on the Invitrogen Luminex xMAP™ INTELLIFLEX DR-SE System. Data for IL-8 (CXCL8) and MCP-1 (CCL2) are shown here as an example. Data analysis was performed using the ProcartaPlex and QuantiGene Plex Data Analysis Apps on the Thermo Fisher Connect platform.
Additional resources for immuno-oncology research
Download white paper:
Detection of soluble immune checkpoint molecules with ProcartaPlex multiplex panels
Download posters:
Cancer Pathways Posters for Immuno-oncology Research
Explore additional resources and tool for Immuno-Oncology Research
